Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Conspectus “Drug resistance is an unavoidable consequence of the use of drugs; however,
the emergence of multi-drug resistance can be managed by accurate diagnosis and tailor …

Insufficient development of new antibiotics and the rising resistance of bacteria to those that
we have are putting the world at risk of losing the most widely curative class of medicines …

Background The triple burden of COVID-19, tuberculosis and human immunodeficiency
virus is one of the major global health challenges of the twenty-first century. In high burden …

Hydroxychloroquine (HCQ) is a promising candidate for Coronavirus disease of 2019
(COVID‐19) treatment. The optimal dosing of HCQ is unknown. Our goal was to integrate …

Tuberculosis (TB) remains a leading cause of infectious death worldwide, and poverty is a
major driver. Clinically, TB presents as “latent” TB and active TB disease, and the treatment …

Rationale Bedaquiline has been classified as a group A drug for the treatment of multidrug-
resistant tuberculosis (MDR-TB) by the World Health Organization; however, globally …

The ability of Mycobacterium tuberculosis (Mtb) to resist and tolerate antibiotics complicates
the development of improved tuberculosis (TB) chemotherapies. Here we define the Mtb …

Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

The widespread use of antibiotics has placed bacterial pathogens under intense pressure to
evolve new survival mechanisms. Genomic analysis of 51,229 Mycobacterium tuberculosis …